Published in Oncoimmunology on January 01, 2014
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. Oncoimmunology (2015) 0.85
Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology (2015) 0.83
Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology (2016) 0.81
Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res (2015) 0.78
T cells compete by cleaving cell surface CD27 and blocking access to CD70-bearing APCs. Eur J Immunol (2015) 0.78
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. Pharmacol Ther (2017) 0.76
Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood (2007) 1.15
Role of CD27/CD70 pathway of activation in immunity and tolerance. J Leukoc Biol (2010) 1.13
Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies. PLoS One (2008) 1.09
Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. J Immunother (2010) 1.06
Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. J Immunol (2013) 0.98
CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res (2012) 0.98
Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clin Cancer Res (2012) 0.93
Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice. Biochem Biophys Res Commun (2010) 0.92
Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo. Int J Cancer (2006) 0.87